This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Lung Cancer Foundation's 360 Community Hospital Program Improving Individualized Standard Of Care For Patients

The program's process focuses on early detection, diagnosis, treatment and treatment monitoring, and patient follow up. Critical in the program's standard of care is ensuring all patients receive molecular testing, which uses DNA, RNA and proteins to test for specific states of disease. In lung cancer, molecular testing is used to determine potential patient response to targeted therapy.

The LCF has received generous support from a number of distinguished industry partners, including GE Healthcare, Pfizer and Boehringer-Ingelheim. GE Healthcare provided in-kind services from its oncology solutions division to help create the program's flow and metrics. The LCF is working with Boehringer-Ingelheim and Pfizer in partnership to broaden the overall awareness of multi-disciplinary collaborations that incorporate personalized testing to initiate timely and appropriate lung cancer treatments. Boehringer-Ingelheim also leads the letstestnow.com campaign, set up to improve patient outcomes through a multidisciplinary approach to biomarker testing in advanced non-small cell lung cancer.

"Every community hospital that joins us and implements this new multi-disciplinary, patient-centric approach to standard of care will be given a formal seal of excellence awarded by the LCF, signifying that no lung cancer patient is left behind," Addario said.

The pilot program launches during a time when an estimated 228,190 new cases of lung cancer will be diagnosed in the United States this year. The American Cancer Society also estimates 159,480 Americans will die from the disease this year. 

The facts about Lung Cancer cannot continue to go unnoticed:

  • In the last 45 years 50 million people worldwide have died from lung cancer.
  • Every day 450 more die, 19 every hour and one every three minutes will die in the US and 1.4 million worldwide every year.
  • It is the leading cancer killer in every ethnic group, and since 1987 lung cancer has killed more women every year than breast cancer.
  • Yet the five-year survival rate for lung cancer is only 15.7 percent, and it has remained unchanged for more than 40 years.
  • This staggering loss of life has gone unnoticed too long, and the Bonnie J. Addario Lung Cancer Foundation is on a mission to change that.
  • The LCF funds clinical research that leads to life-saving discoveries and treatments and provides critical support services and educational programs to empower patients and create hope. 

"The Foundation is powering progress through ground-up initiatives, educating patients to identify solutions and make timely and meaningful change," Addario said. "The LCF is empowering patients to take a seat at the table wherever discussions are being made about their care. We are committed to improving the standard of care and believe that chronically managed lung cancer using molecular testing to determine personalized therapies is the future of lung cancer treatment and the pathway to increasing the survival rate."

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,276.15 +143.45 0.79%
S&P 500 2,114.91 +10.41 0.49%
NASDAQ 5,001.2030 +37.6760 0.76%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs